Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$26.04 -1.64%

-$0.38 today

Market cap
$1.81B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 1.02M

Average 0.71M

ZYME Sales of Investments

Cash received from selling or redeeming investments.

Zymeworks Inc.NASDAQ: ZYME

Sales of Investments · Q3 FY2026 · quarter ended Sep 2026

Sales of investments growth accelerates

Q3 FY2026 sales of investments of $142.32M rose 297.2% year over year, ahead of the +68.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 78.8% from the prior quarter.

Context

  • Sales of investments amounted to 212.4% of revenue in FY2025, down 214.3 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +297.2% holds above the trailing-twelve-month pace of +68.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$142.32M+78.8% QoQ
Last fiscal yearDec 2025
$225.08M-30.9% YoY
LTMSep 2026
$353.02M+68.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+297.2%——
1 year-30.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
225.08M USD
Year-over-year change
-30.9%
4-year CAGR
+3.9%

Sales of Investments vs competitors

How ZYME compares with its peers on the latest reported figures

  • ZYME's LTM Sep 2026 sales of investments of $353.02M is the 4th largest of the 11 companies compared; the peer median is $117.92M.
  • Its year-over-year change of +68.0% is the highest of 8, against a peer median of -21.3%.
  • Sales of investments amounts to 132.7% of revenue for ZYME, versus a peer median of 83.7%.
ZYME Competitors Peer median
Sales of Investments for ZYME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$614.95M +3.0%+30.4%87.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$502.67M -21.3%+28.6%448811.6%
XNCRXencor, Inc.LTM Jun 2026$385.46M -16.6%+11.7%367.2%
ZYMEZymeworks Inc.LTM Sep 2026$353.02M +68.0%—132.7%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$132.5M -49.2%+10.0%372.8%
MGNXMacroGenics, Inc.LTM Mar 2026$125.44M -4.7%-21.0%79.9%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$110.41M -38.6%-2.0%—
IMNMImmunome, Inc.LTM Sep 2026$54M -81.1%——
CBIOCrescent Biopharma, Inc.LTM Mar 2026$0 ——0.0%
CGENCompugen Ltd.LTM Dec 2025$0 —+3.4%0.0%
ADCTADC Therapeutics S.A.LTM Mar 2026$0 ——0.0%
Peer median (excluding ZYME) $117.92M-21.3%+10.0%83.7%

Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(211.84M)124.34M(118.67M)(122.7M)(81.13M)
Depreciation & Amortization9.58M12M17.31M11.19M11.11M
Deferred Income Tax(953K)1.94M(757K)691K945K
Stock-Based Compensation10.76M4.02M8.1M17.79M28.03M
Change in Working Capital393K4.02M(25.55M)(30.95M)7.5M
Accounts Receivables(266K)(17.51M)13.92M(36.36M)51.2M
Inventory00000
Accounts Payables16.48M26.48M(44.77M)14.34M(23.65M)
Other Working Capital(15.82M)(4.96M)5.3M(8.93M)(20.05M)
Other Non-Cash Items(387K)(2.21M)1.27M13.93M532K
Operating Cash Flow(192.45M)144.11M(118.3M)(110.04M)(33.01M)
Capital Expenditures(13.29M)(13.13M)(4.08M)(3.07M)(1.52M)
Acquisitions (Net)00000
Purchases of Investments(35.08M)(40.72M)(553.25M)(283.74M)(196.06M)
Sales of Investments192.96M(40.72M)350.07M325.57M225.08M
Other Investing Activities(881K)40.72M(1.6M)(1.08M)0
Investing Cash Flow144.6M(53.85M)(207.25M)38.76M26.66M
Debt Repayment(17K)(14K)(21K)(14K)0
Common Stock Issued0107.53M76.1M023.32M
Common Stock Repurchased000(30.05M)(41.7M)
Dividends Paid00000
Other Financing Activities8.03M1.06M5.77M9.61M(181K)
Financing Cash Flow8.01M108.58M81.85M(20.45M)(18.56M)
Effect of Forex Changes(325K)203K354K286K(45K)
Net Change in Cash(40.17M)199.05M(243.36M)(91.45M)(24.95M)
Free Cash Flow(205.74M)130.98M(122.38M)(113.11M)(34.53M)

Zymeworks Inc.

NASDAQ:ZYME

Intrinsic Alpha fair value

Locked

Current Price

$26.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.